Olaparib in an ovarian cancer patient with end-stage renal disease and hemodialysis

PURPOSE: For patients with severe renal impairment (CrCl ≤ 30 ml/min) or end-stage renal disease (ESRD), olaparib intake is not recommended as the pharmacokinetics and safety of olaparib have not been evaluated in this patient group. Therefore, this valuable patient group is generally excluded from...

Descripción completa

Detalles Bibliográficos
Autores principales: Baum, Joanna, Zickler, Daniel, Bolbrinker, Juliane, Richter, Rolf, Braicu, Elena Ioana, Grabowski, Jacek, Sehouli, Jalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068645/
https://www.ncbi.nlm.nih.gov/pubmed/36947209
http://dx.doi.org/10.1007/s00280-023-04514-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10068645/
https://www.ncbi.nlm.nih.gov/pubmed/36947209
http://dx.doi.org/10.1007/s00280-023-04514-x

Ejemplares similares